secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001013762-25-002786
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada licenses NDV-01 from Trigone for $3.5M + 3M shares; Phase 2 data at AUA April 2025
--------------------------------------------------------------------------------

- Upfront: $3.5M cash + 3,017,420 shares (10% of outstanding) for exclusive worldwide rights (ex-India, Israel, S. Africa).
- Up to $200M in development/regulatory/sales milestones + 3% royalty on net sales.
- NDV-01 is sustained-release gemcitabine/docetaxel for NMIBC; Phase 2 topline data at AUA April 26-29, 2025.
- Shares locked up for 12 months; Trigone must vote as board recommends.
- Relmada must spend ≥$5M/year on R&D/commercialization from 2026; Trigone can terminate if not.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000101376225002786/0001013762-25-002786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000101376225002786/ea0235681-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-002786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer